FTC Sues to Block Proposed $3.5 Billion Covetrus-MWI Merger
By Katherine Hamilton
Covetrus has been sued by the Federal Trade Commission to block the company from acquiring rival MWI Veterinary Supply.
Covetrus, which provides supplies to veterinarians, agreed in February to acquire Cencora's MWI animal-health business in a deal worth $3.5 billion.
The FTC is alleging the transaction would merge two of the biggest suppliers in the vet-clinic distribution industry, potentially driving up costs and hurting competition.
Covetrus responded to the suit Friday saying the merger would improve the economics of veterinary practices. By combining, Covetrus and MWI would make it easier and more efficient for vets to access products, the company said.
In its suit, the FTC said the emergence of Vetcove, an online platform allowing vets to compare prices across distributors, has fueled more pricing competition among suppliers. The market concentration that would allegedly occur from a merger renders the deal unlawful under antitrust law, the FTC said.
The FTC vote to authorize staff to seek a permanent injunction to block the proposed deal was 2-0.
Covetrus said it was confident in the merits of the proposed deal and that it was prepared to defend them in court.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
November 13, 2026 13:23 ET (18:23 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

4 Growth Stocks to Buy While They’re Still Undervalued

3 of the Best Core Stocks to Own

3 Great New ETFs From 2026

The 10 Best Companies to Invest in Now

